Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014757 | 0.99 | PTPN11 (0.50) | POLBSMN1; SMN2PTPN11MAPTNR3C1 | |
| SCHEMBL1012872 | 0.94 | PTPN11 (0.52) | POLBSMN1; SMN2PTPN11MAPTHSD11B1 | |
| SCHEMBL1014776 | 0.89 | POLB (0.64) | POLBSMN1; SMN2MAPTNR3C1HSD11B1 | |
| SCHEMBL1017870 | 0.89 | POLB (0.64) | POLBSMN1; SMN2MAPTNR3C1HSD11B1 | |
| SCHEMBL1013784 | 0.88 | POLB (0.53) | POLBSMN1; SMN2MAPTNR3C1HSD11B1 | |
| SCHEMBL1014719 | 0.88 | POLB (0.53) | POLBSMN1; SMN2MAPTNR3C1HSD11B1 | |
| SCHEMBL1014028 | 0.87 | POLB (0.61) | POLBSMN1; SMN2MAPTNR3C1HSD11B1 | |
| SCHEMBL1014425 | 0.84 | HSD11B1 (0.61) | POLBSMN1; SMN2MAPTNR3C1HSD11B1 | |
| SCHEMBL1015708 | 0.84 | POLB (0.52) | POLBSMN1; SMN2MAPTNR3C1HSD11B1 | |
| SCHEMBL1015182 | 0.84 | HSD11B1 (0.61) | POLBSMN1; SMN2MAPTNR3C1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102066335-A | Substituted pyrimidin-5-carboxamides 281 | ASTRAZENECA AB | 2011-05-18 | — | — | CN | disclosed |
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | POLB 2006/4885SMN1; SMN2 2203/4885PTPN11 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.